Acronym:
ORAL MUCOSITIS
ACTRN/NCT /ethics:
Scientific title:
Summary of trial and patient characteristics
Cancer Type | Head and Neck | ||
---|---|---|---|
Trial Type | Treatment | ||
Phase | Phase II, Phase I | Tumour Stream | Head and Neck |
Age Range | 18 years and older | Cancer Stage | Clinical Trials - Cancer Stage |
Sex | Both | Anticipated Start Date | |
Molecular Target | Anticipated End Date |
Cancer Type | Head and Neck |
---|---|
Trial Type | Treatment |
Phase | Phase II, Phase I |
Age Range | 18 years and older |
Sex | Both |
Molecular Target | |
Tumour Stream | Head and Neck |
Cancer Stage | Clinical Trials - Cancer Stage |
Anticipated Start Date | |
Anticipated End Date |
Trial Summary
A phase 1b/2, multicanter, randomised study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ST-617 for the attenuation of oral mucositis in patients receiving chemoradiation for head and neck cancer.
Lay Summary
Sponsor / Cooperative group
Participating Hospitals
Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
---|---|---|---|---|---|
Flinders Medical Centre | Alex Scott-Hoy | alex.scott-hoy@sa.gov.au | 08 8204 4830 | Shawgi Sukumaran | Recruitment on Hold |